KR20250079183A - 소토라십 투약 요법 - Google Patents

소토라십 투약 요법 Download PDF

Info

Publication number
KR20250079183A
KR20250079183A KR1020257013939A KR20257013939A KR20250079183A KR 20250079183 A KR20250079183 A KR 20250079183A KR 1020257013939 A KR1020257013939 A KR 1020257013939A KR 20257013939 A KR20257013939 A KR 20257013939A KR 20250079183 A KR20250079183 A KR 20250079183A
Authority
KR
South Korea
Prior art keywords
cancer
patient
sotorasib
dose
rosuvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257013939A
Other languages
English (en)
Korean (ko)
Inventor
브렛 이. 후크
판리 카르도나
Original Assignee
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크 filed Critical 암젠 인크
Publication of KR20250079183A publication Critical patent/KR20250079183A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257013939A 2022-09-30 2022-12-16 소토라십 투약 요법 Pending KR20250079183A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263411789P 2022-09-30 2022-09-30
US63/411,789 2022-09-30
PCT/US2022/053130 WO2024072437A1 (en) 2022-09-30 2022-12-16 Sotorasib dosing regimen

Publications (1)

Publication Number Publication Date
KR20250079183A true KR20250079183A (ko) 2025-06-04

Family

ID=85158814

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257013939A Pending KR20250079183A (ko) 2022-09-30 2022-12-16 소토라십 투약 요법

Country Status (9)

Country Link
US (1) US20260083741A1 (https=)
EP (1) EP4593837A1 (https=)
JP (1) JP2025533334A (https=)
KR (1) KR20250079183A (https=)
AU (1) AU2022479909A1 (https=)
JO (1) JOP20250064A1 (https=)
MX (1) MX2025003741A (https=)
TW (1) TW202415380A (https=)
WO (1) WO2024072437A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013557A (es) * 2021-05-18 2023-11-29 Amgen Inc Pauta posologica de sotorasib.

Also Published As

Publication number Publication date
TW202415380A (zh) 2024-04-16
US20260083741A1 (en) 2026-03-26
EP4593837A1 (en) 2025-08-06
AU2022479909A1 (en) 2025-02-06
WO2024072437A1 (en) 2024-04-04
MX2025003741A (es) 2025-05-02
JOP20250064A1 (ar) 2025-03-25
JP2025533334A (ja) 2025-10-06

Similar Documents

Publication Publication Date Title
US20220323446A1 (en) Sotorasib dosing regimen
US20250375452A1 (en) Sotorasib dosing regimen
CN113645975A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
IL295514A (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
Beumer et al. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short‐bowel syndrome
CN113423402A (zh) 癌症治疗
US20260083741A1 (en) Sotorasib dosing regimen
CA3269092A1 (en) Sotorasib dosing regimen
WO2023002983A1 (ja) Ｆｇｆｒ阻害薬に対する感受性の判定方法
AU2023366820A1 (en) Methods of treating cancer with sotorasib
CN113645974A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
EA053101B1 (ru) Способы лечения рака с помощью соторасиба
TW202342766A (zh) 用於癌症治療之精準療法
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CN116981462A (zh) 索托拉西布给药方案
HK40081735A (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
CN118043049A (zh) 用于治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
JPWO2010074240A1 (ja) 化学療法の治療効果予測方法
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40013982A (en) Cancer treatment

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000